Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Tullahoma, Tennessee


Purpose:

The purpose of this study is to demonstrate the ability of tedisamil to convert atrial fibrillation or flutter into normal sinus rhythm (NSR) in female patients.


Criteria:

Inclusion Criteria: - Willing to sign informed consent before screening examinations are performed and before the study drug is administered - Females > 18 years of age - Subjects with documented (60 second rhythm strip) symptomatic atrial fibrillation or flutter (duration > 3 hours and < 45 days) at the time of randomization - Subjects who are in no distress and hemodynamically stable (supine systolic blood pressure > 90 mmHg and diastolic blood pressure < 105 mmHg) Exclusion Criteria: - Pregnancy and lactation - Acute myocardial infarction and cerebrovascular accidents - Coronary syndromes and congestive heart failure (CHF) New York Heart Association (NYHA) IV - Life-threatening ventricular arrhythmias and electrocardiogram (ECG) abnormalities - Concurrent antiarrhythmic treatments


NCT ID:

NCT00126022


Primary Contact:

Study Director
Global Clinical Director Solvay
Solvay Pharmaceuticals


Backup Contact:

N/A


Location Contact:

Tullahoma, Tennessee
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: December 17, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.